Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

Hepatology · 2022 · PMC9790568 · PMID 35220605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We also found that the percent of patients with NAFLD treated with lipid‐lowering medication (statins and/or fibrates) was higher in subtype A (24%) than in subtypes B (17%) and C (17%), although it did not reach statistical significance (Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.